By leveraging existing GWAS and eQTL resources, transcriptome-wide association studies 1 (TWAS) have achieved many successes in identifying trait-associations of genetically-regulated 2 expression (GREX) levels. TWAS analysis relies on the shared GREX variation across GWAS 3 and the reference eQTL data, which depends on the cellular conditions of the eQTL data. 4 Considering the increasing availability of eQTL data from different conditions and the often 5 unknown trait-relevant cell/tissue-types, we propose a method and tool, IGREX, for precisely 6 quantifying the proportion of phenotypic variation attributed to the GREX component. IGREX 7 takes as input a reference eQTL panel and individual-level or summary-level GWAS data. Using 8 eQTL data of 48 tissue types from the GTEx project as a reference panel, we evaluated the 9 tissue-specific IGREX impact on a wide spectrum of phenotypes. We observed strong GREX 10 effects on immune-related protein biomarkers. By incorporating trans-eQTLs and analyzing 11 genetically-regulated alternative splicing events, we evaluated new potential directions for 12 TWAS analysis. 13 * Correspondence should be addressed to Jin Liu (jin.liu@duke-nus.edu.sg) and Can Yang (macyang@ust.hk) Genome-wide association studies (GWAS) have successfully identified tens of thousands of 15 unique associations between single-nucleotide polymorphisms (SNPs) and a wide range of 16 complex traits/diseases (http://www.ebi.ac.uk/gwas/). More than 90% of identified risk 17 variants are located in non-coding regions [1] , making it challenging to understand their 18 functional mechanisms. Increasing evidence [2, 3, 4, 5, 6, 7, 8, 9] has suggested that many of 19 those risk variants may affect traits/diseases via the modulation of their cis gene expression 20 levels. For example, a study of 18 complex traits revealed an enrichment for expression 21 quantitative trait loci (eQTLs) in 11% of 729 tissue-trait pairs [10]. There is great interest in 22 precisely characterizing the specific role of genetically regulated gene expression (GREX) in 23 human traits and diseases.
Introduction
and CoMM [22] . Through applications to a wide variety of phenotypes, these methods have 45 successfully identified specific gene-trait associations, whereas a comprehensive and precise 46 evaluation of the impact of GREX variation on various traits and the trait-relevant cellular context is still needed [27] . PVE GREX = tr( G g=1σ 2 α X g (µ g µ T g + Σ g )X T g ) tr( G g=1σ 2 α X g (µ g µ T g + Σ g )X T g +σ 2 γ XX T +σ 2 I n )
.
In the above estimation, the substitution of posterior β g |y g , X r,g accounts for the posterior a subset of X. The estimate of PVE GREX given by IGREX-s is
whereR g =X T gX g /(m − 1) is the estimated LD matrix associated with the g-th gene and 141X g is the corresponding columns ofX. IGREX also allows for the adjustment of covariates 142 including sex, age and genotype principal components (See details in Supplementary Note). 143 Simulation studies. We conducted extensive simulation studies to evaluate the performance 144 of IGREX. For all the simulated data, we fixed n = 4, 000, G = 200, M = 20, 000 (i.e., 100 cis Figure 1 : Simulation studies to compare estimation accuracies of IGREX with other methods. REML and MoM in the legend are abbreviations of the IGREX-i estimation methods. The blue and red dashed lines represent the true values of PVE GREX and PVE Alternative , respectively. We averaged the results over 30 replications and generated box plots for evaluating the estimation performance of: a the three models of IGREX ,REML 0 and MoM 0 when n r was varied at {800, 1000, 2000} and PVE y was varied at{0.1, 0.2, 0.3}; (b) the three models of IGREX when π α = 0.2 and π β was varied at {0.2, 0.5, 0.8}; (c) the three models of IGREX when π β = 0.2 and π α were varied at {0.2, 0.5, 0.8}; (d) the three models of IGREX, REML 0 and MoM 0 when ρ was varied at {0.1, 0.3, 0.5, 0.8}; (e) the three models of IGREX and RhoGE when n r was varied at {800, 1000, 2000}.
WTCCC dataset [33] . We applied IGREX to estimate the tissue-specific PVE GREX of seven hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D) and type 2 diabetes 225 (T2D). The estimates of PVE GREX /h 2 t obtained by REML are shown in Supplementary Fig. 8 .
226
The 71.2% to 11.7% for T1D, as shown in Fig. 3a . Additionally, the tissue-specific comparisons 234 presented in Fig. 3b showed an extensive reduction of PVE GREX in all tissue types for T1D In the following analysis, we used the genotypes of the 635 GTEx samples as the LD reference 245X in the IGREX-s estimation. 246 First, we estimated PVE GREX in 249 proteins with significantly nonzero heritabilities 247 using summary statistics from a plasma protein quantitative trait loci (pQTL) study [38] , as 248 summarized in Fig. 4a . In Supplementary Fig. 10 tissue-specific GREX effect patterns. We found these tissue-specific patterns to be consistent 259 with protein functions. For example, the CFB protein, which is implicated in the growth of 260 preactivated B-lymphocytes, is found to be most associated with GREX in EBV-transformed 261 lymphocytes ( PVE GREX = 22.7%). As another example, the CXCL11 protein has the highest 262 PVE GREX = 20.0% in pancreas, and the CXCL11 gene is often over-expressed in pancreas tissue 263 [39]. We also noted that 6 out of the 9 proteins were immune-related, echoing our previous datasets have higher values in the brain tissues than in other tissue types ( Fig. 5b ). As 273 expected, the statistical power increases with sample size of GWAS ( Fig. 5a ). Additionally, we data sets, we noted the estimated percentages of heritability explained by GREX for all three 278 complex traits are less than 10% (8.7% for schizophrenia, 8.7% for height and 3.7% for BMI in 279 the most expressed tissue types. See Fig. 5c and Supplementary Fig. 15 ).
280
The relatively low GREX contribution to complex traits other than lipid or molecular 281 traits can be attributed to multiple reasons. First, it is known that trans-acting genetic effects 282 can explain a substantial proportion of expression variation [8, 12] . However, trans-eQTL 283 effects are often tissue-specific and can be harder to detect and replicate across studies [45] .
284
In TWAS-types of analysis, generally the prediction of gene expression is based on only cis 285 genetic variants of each gene. As such, the PVE GREX values reported here, also based on only 286 cis genetic variants, may be underestimated. In the next section, we will further explore the 287 contribution of trans-eQTLs. Second, the genetic effects on gene expression may not be steady 288 across the reference GTEx data with largely non-diseased tissues for general purposes and the 289 GWAS data with diseased individuals from specific populations [46] . From this perspective, 290 before analyzing specific complex traits and diseases via TWAS, it would be helpful to first 291 estimate the impact of GREX and select the most informative available eQTL reference data. framework to analyze splicing events and associating 40 complex traits with genetically-predicted splicing quantification, novel putative disease-associated genes were detected [55]. Here, using 325 multi-tissue splicing quantification data from GTEX as reference, we applied IGREX to study 326 the impact of genetically-regulated splicing events on four trait-tissue pairs that were found to 327 have a high PVE GREX /h 2 t . We estimated the proportion of phenotypic variation explained by 328 genetically-regulated splicing to be 12.5%, 13.5%, 1.0% and 1.1% for LDL in liver, TC in liver,
329
SCZ in amygdala and SCZ in cerebellar hemisphere, respectively. Unlike eQTLs that are often 330 found to be near transcription starting sites, most of the sQTLs were found to be enriched 331 within gene bodies, in particular within the introns they regulate, and have little to no effects 332 on cis gene expression levels [55, 56] . In other words, sQTLs are often independent of eQTLs. Figure 6 : Comparison of PVE GREX /h 2 t 's estimated with only local SNPs and those estimated with additional trans-eQTLs. (a) Estimated PVE GREX /h 2 t of 13 datasets in blood. All these datasets have significant PVE GREX /h 2 t in blood at 0.05 nominal level using only local SNPs. (b) Estimated PVE GREX /h 2 t of two largest SCZ data sets in 13 GTEx brain tissues. All these tissues have significant PVE GREX /h 2 t at 0.05 nominal level in both datasets using only local SNPs.
Discussion
suggests the attenuated impact on downstream phenotypes (e.g, height and SCZ), which is consistent with the result from a pioneer study [57] . However, we noted that the PVE GREX 371 estimates could be improved. A substantial amount of expression heritability is explained 372 by trans-acting genetic factors while current TWAS and IGREX analyses are mainly using 373 only cis-eQTLs. We explored the potential of incorporating trans-eQTLs in TWAS analysis 374 by re-estimating PVE GREX for selected traits in blood tissues with significant trans-eQTLs 375 independently derived from the blood-based eQTLGen Consortium. We observed consistent 376 increases in PVE GREX for blood-related traits. In contrast, such an increase was not observed in 377 the PVE GREX estimates for other tissue types, again illustrating the importance of considering 378 trait-relevant tissue types/conditions in the TWAS-type of analyses. Additionally, we extended 379 the IGREX analysis to quantify the impact of genetically-regulated alternative splicing events 380 on selected traits. Our results suggested the potential for extending TWAS-type of analysis to 381 integrate reference multi-omics QTL data with GWAS in mapping novel disease/trait-associated 382 genes with mechanisms via other omics traits (such as splicing, methylation, protein, etc.).
383
A key assumption in applying IGREX or TWAS methods with a general-purpose eQTL 384 data as reference is the existence of steady-sate component in GREX, i.e., the genetic effects 385 on gene expression β g are shared across the eQTL reference and GWAS data. However, there 386 are many situations in which this assumption is violated. For example, it has been observed 387 that CAD-risk SNPs have a larger overlap with cis-eQTLs isolated from disease-relevant tissues 388 than those from GTEx tissues [46] , implying the existence of a dynamic component. In the 389 presence of this dynamic component, the accuracy of PVE GREX based on GTEx is reduced.
390
In those cases, we suggest exploring other trait-relevant or condition-specific eQTL reference 391 panels using IGREX for a better understanding of the role of GREX and before conducting 392 TWAS analysis.
393

Methods
394
The IGREX-i for individual-level GWAS data. First, let D r = {Y, X r } denote the 395 reference data set from an eQTL study, where Y ∈ R nr×G is the gene expression matrix, 396 X r ∈ R nr×M is the genotype matrix, n r is the sample size of the eQTL study, G is the 397 number of genes and M is the number of single-nucleotide polymorphisms (SNPs). Suppose 398 we have individual-level GWAS data D i = {t, X} comprised of phenotype vector t ∈ R n and 399 genotype matrix X ∈ R n×M , where n is the GWAS sample size. For g = 1, ..., G, we let the g-th gene expression vector y g ∈ R nr denote the corresponding column of Y, local genotype 401 matrices X r,g ∈ R nr×Mg and X g ∈ R n×Mg denote the corresponding M g columns in X r and 402 X, respectively, where M g is the number of local SNPs for g-th gene. To make the notation 403 uncluttered, we further assume that X r,g and X g have been standardized and both y g and t 404 have been properly adjusted for covariates. The complete model that accounts for covariates is 405 described in the Supplementary Materials. Now, we consider linear model (1) that associates 406 the gene expression vector y g to X r,g : 407 y g = X r,g β g + e r,g , where β g is an M g × 1 vector of genetic effects on the gene expression levels, e r,g ∼ N (0, σ 2 r,g I nr )
408 is a vector of independent noise and I is the identity matrix with the subscript being its 409 size. Assuming that there is a steady-state component in gene expression regulated by genetic 410 variants, individuals in D r and D i share the same β g . Hence, the GREX in D i can be evaluated 411 by X g β g . Then, we assume that the phenotype t can be decomposed into two parts, i.e., the 412 genetic effects via GREX and the genetic effects through alternative pathways, as in model (2):
where α g is the effect of X g β g on t, γ is an n × 1 vector of alternative genetic effects and 414 ∼ N (0, σ 2 I n ) is a vector of independent errors. The term G g=1 α g X g β g can be viewed as 415 the overall impact of GREX on the phenotype and Xγ represents the alternative impact of 416 genotypes on the phenotype. Given a genotype vector x ∈ R M and a phenotype t ∈ R, the 417 impact of GREX can be quantified by the proportion of variance explained by the GREX 418 component:
where x g is the subvector of genotype x corresponding to the g-th gene.
420
To estimate PVE GREX , we introduce the following probabilistic structure for the effects in 421 model (1) and (2):
which is motivated by a recent theoretical justification [58] for heritability estimation on a 423 mis-specified linear mixed model (LMM). This prior specification in (4) provides a great com-putational advantage as well as a stable performance for IGREX under model mis-specification, as demonstrated in the simulation studies.
426
The proposed method for individual-level GWAS data, IGREX-i, provides a two-stage 427 framework for estimating PVE GREX . In the first stage, we estimate the parameters σ 2 βg and σ 2 r,g 428 in model (1) via a fast expectation-maximization (EM)-type algorithm, the parameter-expanded 429 EM (PX-EM) algorithm [59] . Based on the estimates, denoted asσ 2 βg andσ 2 r,g , the posterior 430 distribution of β g is given by
In the second stage, we treat the posterior distribution obtained in (5) as the prior distribution 432 of β g in model (2). This substitution naturally accounts for the uncertainty in estimating 433 β g which has been captured by Σ g . To evaluate the covariance of t, we first note that 434 E(t|α) = G g=1 α g X g µ g and Cov(t|α) = G g=1 α 2 g X g Σ g X T g + σ 2 γ XX T + σ 2 I n ; then, using the 435 law of total expectation and total variance, we obtain E(t) = E(E(t|α)) = 0 and 436
respectively. By observing the form of (6), it is clear that the i-th diagonal element of 437 G g=1 σ 2 α X g (µ g µ T g + Σ g )X T g and σ 2 γ XX T represents the variance explained by GREX and 438 alternative genetic effects, respectively. Therefore, the PVE GREX defined in (3) can be estimated 439 by 440
whereσ 2 α ,σ 2 γ andσ 2 are the estimated values of σ 2 α , σ 2 γ and σ 2 , respectively.
441
IGREX-i provides two methods for estimating the parameters and PVE GREX in the sec-442 ond stage. Let ψ = σ 2 α , σ 2 γ , σ 2 T be the vector of parameters to be estimated, K α = 443 G g=1 X g (µ g µ T g + Σ g )X T g and K γ = XX T . The first method is based on MoM, which minimizes 444 the distance between the second moment of t at the population level and that at the sample 445 level f (ψ) = ||tt T − (σ 2 α K α + σ 2 γ K γ + σ 2 I n )|| 2 . By setting ∂f (ψ) 
The solution of Equation (8) is given byψ = S −1 q. And the variance-covariance matrix ofψ 449 is given by Cov(ψ) = S −1 Cov(q)S −1 using the sandwich estimator. Then, the standard error 450 of PVE GREX can be obtained by the delta method (see Supplementary Materials) . The second 451 method applies the restricted maximum likelihood (REML) by further assuming the normal 452 distribution of t: t ∼ N (0, σ 2 α K α + σ 2 γ K γ + σ 2 I n ). The variance components are estimated by 453 the Minorization-Maximization (MM) algorithm [60] .
454
The IGREX-s for summary-level GWAS data. The special formulation of method of 455 moments allows IGREX to be extended (IGREX-s) to handle summary-level GWAS data (i.e. by regressing x j on t. By assuming that z-scores are calculated from a standardized genotype 460 matrix X, we have x T j x j = n. Besides, the polygenicity assumption implies thatσ 2 j ≈σ 2 t , where 461σ 2 t is the estimate of Var(t). Hence, we have
and PVE GREX defined in (3) can be estimated by
whereR g =X T gX g /(m − 1) is the estimated LD matrix associated with the g-th gene andX g 464 is the corresponding columns of a reference genotype matrixX. In practice,X ∈ R m×M can be 465 the genotype matrix either from the GTEx Project or the 1000 Genomes Project. Now, we 
The terms on the left hand side do not involve t and thus can be approximated usingX , whereK α = 470 G g=1X g (µ g µ T g + Σ g )X T g . Other terms on the left hand side can be approximated in the same way. For the right hand side, each term can be approximated usingR g and z-scores from approximation (9): t T K α t ≈ nσ 2 t g z T g (µ g µ T g +Σ g )z g , where z g ∈ R Mg is the vector of z-scores corresponding to the g-th gene; tr(Kα) n t T t ≈ nσ 2 t tr( g (µ g µ T g + Σ g )R g ); t T K γ t ≈ nσ 2 t M j=1 z 2 j ; 474 and tr(Kγ ) n t T t ≈ nσ 2 t . With these approximations, Equation (11) 
